Celmatix Company
.jpg)
Celmatix is a next-generation women’s health company transforming the way women and their physicians leverage genomics and data to make more informed, proactive reproductive health decisions. Their products include Polaris, Fertilome genetic test and MyFertility Compass. Celmatix's lead program aims to protect the ovary from chemotherapy-induced ovarian failure (CIOF). For the 1.9 million pre-menopausal women diagnosed with cancer, the need is critical, urgent, and unmet.
.png)
.jpg)
Founded Date:
01-01-2009
Total Funding:
$53,660,000
Investor Type:
Company
Employee Number:
11-50
Investment Stage:
N/A
Funding Status:
Early Stage Venture
Number Of Exists:
Venture - Series Unknown
Technology:
Longevity FemTech
Last Funding Type:
Venture - Series Unknown
Investors Number:
7
Last Funding Date:
2019-04-01
Industry:
Reproductive Health & Contraception
Headquarters:
New York, New York, United States
Estimated Revenue:
$10M to $50M